nirmatrelvir / ritonavir
Paxlovid is a medicine used for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
Paxlovid contains two active substances, PF-07321332 and ritonavir, in two different tablets.
Paxlovid : EPAR - Medicine overview (PDF/128.98 KB)
First published: 28/01/2022
Last updated: 07/03/2023
Paxlovid : EPAR - Risk-management-plan (PDF/4.18 MB) (updated)
First published: 27/01/2022
Last updated: 21/09/2023
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
COVID-19 virus infection
|Anatomical therapeutic chemical (ATC) code||
Pfizer Europe MA EEIG
|Date of issue of marketing authorisation valid throughout the European Union||
Boulevard de la Plaine 17
20/07/2023 Paxlovid - EMEA/H/C/005973 - II/0042
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID 19.